EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)

Annals of the Rheumatic Diseases

Volumn 68, Issue 5, 2009, Pages 620-628

  Kowal Bielecka, O ^a   Landewe R ^b   Avouac, J ^a,c   Chwiesko, S ^a   Miniati, I ^d   Czirjak, L ^e   Clements, P ^f   Denton, C ^g   Farge, D ^h   Fligelstone, K ⁱ   Foldvari I ^j   Furst, D E ^f   Muller Ladner U ^k   Seibold, J ^l   Silver, R M ^m   Takehara, K ^j,n   Garay Toth, B ^o   Tyndall, A ^p   Valentini, G ^q   Van Den Hoogen, F ^r   Wigley, F ^s   Zulian, F ^j,t   Matucci Cerinic, Marco ^d   Wollheim, F ^j   Scheja, A ^j   Nevskaya, T ^j   Ananieva, L ^j   Nassonov, E ^j   Allanore, Y ^j   Kahan, A ^j   Hachulla, E ^j   Launay, D ^j   Herrick, A ^j   Van Laar, J ^j   Chizzolini, C ^j   Ciurtin, C ^j   Opris, D ^j   Ionescu, R ^j   Capraru, M ^j   Rednic, S ^j   Distler, O ^j   Simsek, I ^j   Dinc, A ^j   Inanc, M ^j   Graninger, W ^j   Kotter, I ^j   Gran, J T ^j   Midvedt, O ^j   Kucharz, E ^j   Krasowska, D ^j   Majdan, M ^j   Sierakowski, S ^j   Salvador, M J ^j   Pereira Da Silva, J A ^j   Damjanov, N ^j   Carreira, P ^j   Garcia De La Pena Lefebvre, P ^j   Szucs, G ^j   Szekanecz, Z ^j   Becvar, R ^j   Pinto, P ^j   Coelho, P ^j   Novak, S ^j   Walker, U ^j   Aringer, M ^j   Glaenz, T ^j   Neumann, C H ^j   Emmert, S ^j   Worm, M ^j   Riemekasten, G ^j   Krieg, T ^j   Hunzelmann, N ^j   Steinbrink, K ^j   Sunderkotter, C ^j   Heitmann, S ^j   Foldvari, I ^j   Iannone, F ^j   Lapadula, G ^j   Airn P ^j   Giacomelli, R ^j   Scorza, R ^j   Rizzi, M ^j   Indiveri, F ^j   Riccieri, V ^j   Rozman, B ^j   Jun, Jae Bum ^j   Derk, C ^j   Sandorfi, N ^j   Jimenez, S ^j   Tikly, M ^j   Alhasani, Saad ^j   Shoenfeld, Y ^j   Balbir Gurmann, A ^j   more..

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RDU   (France)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF PÉCS   (Hungary)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RFH   (United Kingdom)

^h Internal Medicine Department   (France)

ⁱ Scleroderma Association   (United Kingdom)

^j Klin Eilbek ^*

^k Rheumatology Department   (Germany)

^l Rheumatology Department   (United States)

^m MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁿ USM   (Japan)

^o Scleroderma Association   (Hungary)

^p UH   (Switzerland)

^q SU   (Italy)

^r SINT MAARTENSKLINIEK   (Netherlands)

^s JOHNS HOPKINS UNIVERSITY   (United States)

^t UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; BOSENTAN; CAPTOPRIL; CISAPRIDE; CISAPROST; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; ENALAPRIL; ILOPROST; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; NIFEDIPINE; PLACEBO; PREDNISOLONE; PREDNISONE; PROKINETIC AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG;

APPETITE DISORDER; ARTICLE; BLOATING; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; EUROPE; EXERCISE TEST; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; INTERSTITIAL LUNG DISEASE; JAPAN; KIDNEY DISEASE; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG INJURY; MALABSORPTION; PANCYTOPENIA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; PULMONARY HYPERTENSION; QT PROLONGATION; RAYNAUD PHENOMENON; SCLERODERMA RENAL CRISIS; SKIN DISEASE; SURVIVAL; SYSTEMIC SCLEROSIS; TERATOGENICITY; TREATMENT DURATION; ULCER; ULCER HEALING; UNITED STATES; WALKING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; METHODOLOGY; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; HYPERTENSION, PULMONARY; KIDNEY DISEASES; LUNG DISEASES, INTERSTITIAL; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 66149100618     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.096677     Document Type: Article

References (85)

1. Seibold JR, Furst DE, Clements PJ. Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 1992;19:673-676
2. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-1176 (Pubitemid 39120376)
3. Avouac J, Kowal-Bielecka O, Landewe, Chwiesko S, Miniati I, Czirjak L, et al. EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the Treatment of Systemic Sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. Published Online First: 28 October 2008. doi: 10.1136/ard.2008.095299
4. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
5. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-596 (Pubitemid 29188967)
6. Ettinger WH, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984;77:451-456 (Pubitemid 14073689)
7. Kahan A, Weber S, Amor B, Menkes CJ, Saporta L, Hodara M, et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). Eur Heart J 1983;4(suppl C):123-129
8. Kahan A, Foult JM, Weber S, Amor B, Menkes CJ, Degeorges M. Nifedipine and alpha-1-adrenergic blockade in Raynaud's phenomenon. Eur Heart J 1985;6:702-705
9. Kahan A, Amor B, Menkes CJ, Weber S, Guerin F, Degeorges M. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Angiology 1987;38:333-337 (Pubitemid 17066801)
10. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989;298:561-564 (Pubitemid 19072096)
11. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983;308:880-883
12. Thomas MRH, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, et al. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 1987;117:237-241 (Pubitemid 17128477)
13. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-2655 (Pubitemid 30327186)
14. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-1847 (Pubitemid 32758232)
15. Rhedda A, McCans J, Willan AR, Ford PM. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol 1985;12:724-727 (Pubitemid 15229667)
16. Kahan A, Amor B, Menkes CJ. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985;44:30-33 (Pubitemid 15120419)
17. Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
18. Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-1406
19. Lau CS, Belch JJ, Madhok R, Cappell H, Herrick A, Jayson M, et al. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 1993;11:35-40. (Pubitemid 23050850)
20. McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-47 (Pubitemid 18054520)
21. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-1414
22. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
23. Yardumian DA, Isenberg DA. Rustin M, Belcher G,.Snaith ML, Dowd PM, et al. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-226 (Pubitemid 18170569)
24. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998;(2):CD000953. doi: 10.1002/14651858.CD000953.
25. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-677 (Pubitemid 28214985)
26. Black CM, Halkier SA, Rensen L, Belch JJ, Ullman S, Madhok R, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952-960 (Pubitemid 28457230)
27. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999;26:2173-2178
28. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001;19:503-508 (Pubitemid 32894599)
29. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 2000;132:425-434
30. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis. prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-3993 (Pubitemid 39643947)
31. Seibold JR, Denton CP, Furst DE, Matucci-Cerinic M, Mayes MD, Morganti A, et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc). Arthritis Rheum 2005;52(suppl):http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly. asp?CKey={33F18D9E-8480- 4474-640A-88F04C7721A6}&SKey={E4435789-IC0A-46A4- AC54-634B5E31B449}&MKey={F5B9F43A-15A0-467D-8458-SDF32518B4E3}&AKey= {AA45DD66-F113-4CDD-8E62-01A05F613C0D} (accessed 6 Feb 2009)
32. Seibold JR, Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Kramer F, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 2006;65(suppl II):90.
33. Treinen KA, Louden C, Dennis MJ, Wier PJ. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 1999;59:51-59 (Pubitemid 29078098)
34. Medication guide Tracleer (tra-KLEER) tablets. A10509 Tracleer US Outsert.indd 1, (IN-5247/S) Actelion Pharmaceuticals US, Inc. http://www.fda.gov/medwatch/SAFETY/2004/nov-PI/Tracleer-PI.pdf (accessed Jan 2009).
35. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006;44:113-118 (Pubitemid 43338011)
36. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123 (Pubitemid 32971843)
37. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
38. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359 (Pubitemid 39232254)
39. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, for STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-447
40. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005;171:1292-1297 (Pubitemid 40740738)
41. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2006;3:CD004434.
42. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386 (Pubitemid 36439000)
43. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-1340 (Pubitemid 44620443)
44. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006;36(suppl 3):10-15. (Pubitemid 44179776)
45. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-932 (Pubitemid 43974055)
46. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928 (Pubitemid 46981654)
47. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al, STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056
48. Langleben D, Brock T, Dixon R, Barst R, STRIDE-1 study group. STRIDE 1: effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004;44(suppl):S80-S84. (Pubitemid 40039649)
49. Seibold JR, Langleben D, Badesch D, Naeije R, Galié N, Barst RJ. Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in PAH associated with CTD Ann Rheum Dis 2006;65(suppl II):522.
50. Highland KB, Strange C, Girgis R, Black C. Comparison of sitaxentan and bosentan in pulmonary arterial hypertension associated with connective tissue diseases. Ann Rheum Dis 2006;65(suppl II):393.
51. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007;26:63-69 (Pubitemid 46096748)
52. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157
53. Simonneau G, Burgess G, Parpia T, Badesch D. Sildenafil improves exercise ability and hemodynamics in patients with pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2005;64(suppl III):109.
54. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788
55. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482
56. Food and Drug Administration. Drug approval package: flolan (epoprostenol sodium) injection. 21 November 2001. http://www.fda.gov/cder/foi/nda/2000/20- 444S003-Flolan.htm (accessed Jan 2009).
57. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al, Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804 (Pubitemid 34229650)
58. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al, Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329
59. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al. Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-427
60. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-372 (Pubitemid 26136688)
61. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-1358 (Pubitemid 32537533)
62. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al, Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666
63. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-3970
64. Lopez-Ovejero JA, Saal SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh JH. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979;300:1417-1419 (Pubitemid 9212124)
65. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-357 (Pubitemid 20262820)
66. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-603
67. Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32:1128-1134 (Pubitemid 19237867)
68. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-1619 (Pubitemid 28459919)
69. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-2989 (Pubitemid 35315892)
70. Teixeira L, Mouthon L, Mahr A, Agard C, Cabane J, Guillevin L, for the Groupe Français de Recherche sur la Sclérodermie. Scleroderma renal crisis: presentation, outcome and risk factors based on a retrospective multicenter study of 50 patients. Arthritis Rheum 2006;54(suppl):s743.
71. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810 (Pubitemid 27240763)
72. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;3:CD002095.
73. Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987;93:311-315 (Pubitemid 17097598)
74. Wehrmann T, Caspary WF. Effect of cisapride on esophageal motility in healthy probands and patients with progressive systemic scleroderma. Klin Wochenschr 1990;68:602-607 (Pubitemid 20207854)
75. Kahan A, Chaussade S, Gaudric M, Freitag B, Amor B, Menkes CJ, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol 1991;31:683-687
76. Limburg AJ, Smit AJ, Kleibeuker JH. Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease. Digestion 1991;49:156-160
77. Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 2002;21:43-45 (Pubitemid 34257440)
78. Fiorucci S, Distrutti E, Gerli R, Morelli A. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol 1994;89:550-555 (Pubitemid 24106222)
79. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995;40:1892-1901
80. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461-1467
81. Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y. Methotrexate induced pulmonary injury: serial CT findings. J Thorac Imaging 2003;18:231-236 (Pubitemid 37310726)
82. Lynch JP III, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155:395-420.
83. Hasler WL. Pharmacotherapy for intestinal motor and sensory disorders. Gastroenterol Clin North Am 2003;32:707-732 (Pubitemid 36807589)
84. Karamanolis G, Tack J. Promotility medications - now and in the future. Dig Dis 2006;24:297-307. (Pubitemid 44114423)
85. Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007;25:237-240 (Pubitemid 350194175)